News

PEG10, an ancient, virus-like protein that supports the development of the placenta, appears to also participate in the nerve cell loss associated with amyotrophic lateral sclerosis (ALS), researchers discovered. ALS-causing mutations in the UBQLN2 gene were found to prevent the proper degradation of PEG10. This led to a…

BenevolentAI is advancing BEN-34712, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), to late-stage preclinical studies. The studies are expected to support a future investigational new drug (IND) application, a formal request to the U.S. Food and Drug Administration (FDA) to test a potential new treatment in clinical…

QurAlis soon expects to open its ongoing Phase 1 clinical trial testing QRL-201 in people with amyotrophic lateral sclerosis (ALS) at sites in various European Union countries, including Germany, Belgium, the Netherlands, and Ireland. The company’s announcement comes after these countries reviewed and accepted an application for…

To better understand amyotrophic lateral sclerosis (ALS) and improve patient care, Mitsubishi Tanabe Pharma America (MTPA) is partnering with the ALS/MND Natural History Consortium in collecting real-world data on people with the progressive neurodegenerative disorder. The collaboration will give MTPA access to the consortium’s data repository,…

Modulo Bio has launched with $8 million in funding and a goal to map the neuroimmune system and develop treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The neuroimmune system involves interactions between the nervous system and the immune system, which normally protects the nervous system…

Early treatment with ropinirole, a medication used to treat Parkinson’s disease, may slow disease progression in amyotrophic lateral sclerosis (ALS) patients, according to recently published data from a Phase 1/2 trial. Patients given the therapy showed slower functional declines and delayed disease progression over those who started treatment…

Mutations in the KIF5A gene, associated with some cases of amyotrophic lateral sclerosis (ALS), may lead to impairments in motor unit recovery that are exacerbated with age, according to a recent study. Motor units — nerve cells involved in movement and the muscle fibers they interact with — showed poor…

A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8. But before that, on Sept. 27, an FDA advisory committee will meet to review the potential benefits…

Bill Nuti, the former CEO and chairman of NCR Corporation, is on a mission to eliminate amyotrophic lateral sclerosis (ALS). Nuti, who stepped away from NCR in 2018 after being diagnosed with ALS, has launched CureALS, a nonprofit that will draw on funding, partnerships, data sourcing, and artificial intelligence…

A messenger RNA (mRNA) molecule that provides the instructions for a protein involved in glutamate signaling is not edited as efficiently in amyotrophic lateral sclerosis (ALS) patients as in people without the neurological disorder, according to a new study suggesting its potential use as an ALS biomarker. Glutamate is…